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Tumor Budding As an Index to Predict the Potential Aggressiveness
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Hajime Otsuka, MD,*† Yoichi Otaki, MD,*† Keiju Aokage, MD,*† Shingo Yanagi,*
Kanji Nagai, MD,† Yutaka Nishiwaki, MD,† and Atsushi Ochiai, MD*
Introduction: The term tumor budding has been applied to single
cells or small clusters of up to four cells within the stromal tissue at
the invasive margin of colorectal cancers. This morphologic feature
is increasingly being recognized as an adverse prognostic factor. The
purpose of this study was to evaluate the clinicopathologic signifi-
cance of tumor budding in adenocarcinomas of the lung.
Methods: We investigated the relationship between tumor budding
and clinicopathologic parameters of adenocarcinomas of the lung
and the prognostic significance of tumor budding by reviewing the
cases of 201 consecutive patients who had undergone complete
resection of adenocarcinoma of the lung measuring 30 mm or less in
diameter. We examined immunohistochemical profile of budding
cells (BCs) by immunohistochemical staining with 14 antibodies.
Results: Tumor budding was observed in 78 (43.1%) of the 181
cases with invasive adenocarcinoma. The presence of tumor budding
was significantly associated with lymph node metastasis (p 
0.005), pathologic stage (p  0.001), vascular invasion (p  0.003),
lymphatic invasion (p  0.009), and pleural invasion (p  0.029).
Examination of the relation between the presence of tumor budding
and the predominant histologic subtype revealed that the predomi-
nant papillary subtype was significantly associated with the presence
of tumor budding (p  0.0023), whereas the predominant bronchi-
oloalveolar carcinoma subtype was significantly associated with the
absence of tumor budding (p  0.001). The overall 5-year survival
rates of the group with budding and the group without budding was
67.5% and 88.3%, respectively, and difference was significant (p 
0.0057). Compared with cancer cells forming nests, BCs displayed
reduced expression of cellular adhesion molecule, E-cadherin, and
-catenin (p  0.05 and p  0.05, respectively) and increased
expression of laminin5-2 (p  0.05). However, BCs displayed
reduced expression of differentiation marker, surfactant protein A
(p  0.05). Multivariate analysis revealed that tumor budding was
significant independent prognostic factor of the small-sized adeno-
carcinoma of the lung.
Conclusions: Our data showed that tumor budding in adenocarci-
noma of the lung is a distinct morphologic feature that has biologic
and prognostic significance.
Key Words: Tumor budding, Lung cancer, Small adenocarcinoma,
Prognostic factor, Papillary subtype.
(J Thorac Oncol. 2010;5: 1361–1368)
Lung cancer is the leading cause of cancer deaths world-wide, and the prognosis is generally poor, even if surgery
is successful. The incidence of one type of lung cancer,
adenocarcinoma, has been increasing in recent years.1 Al-
though pure bronchioloalveolar carcinoma (BAC) has been
reported to be the only subtype without any invasive features
and to have an excellent prognosis,2 in some of the patients
with other subtypes of adenocarcinoma sometimes develop
distant metastasis soon after complete surgical resection.3
Even significant fraction of the patients with clinical stage IA
(cT1N0M0) lung adenocarcinoma experience recurrence and
die after curative resection.4 A better understanding of the
changes in tumor cell biology that result in a more aggressive
neoplastic phenotype that have been completely resected may
help identify patients with respectable adenocarcinoma at risk
for recurrent disease and lead to the development of more
effective therapeutic modalities.
The main characteristics of malignancy are invasive
growth by tumor cells and a tendency to infiltrate and me-
tastasize. Crucial steps in the invasive growth process are
detachment at the intercellular junctions between tumor cells
and active invasion of the surrounding stroma. The term
“tumor budding” has been applied to these steps in colorectal
cancer when single cells or small clusters are observed within
the stromal tissue at the invasive margin.5–7 Tumor budding
can be evaluated semiquantitatively by various methods, and
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several study groups have found the results to be reproduc-
ible. Tumor budding is thought to be the morphologic ex-
pression of this crucial step in the invasive growth process,
and, importantly, tumor budding has been shown to be an
independent prognostic factor.8
We have often observed scattered single cells of small
cell clusters in lung adenocarcinoma that are the equivalent of
tumor budding, and we speculate that they are the morpho-
logic expression of the crucial steps in the invasive growth
process, including dedifferentiation and dissociation, the
same as the budding in colorectal cancer. To examine the
pathophysiologic significance of the budding process in small
adenocarcinomas, we reviewed the adenocarcinomas of the
lung measuring 30 mm or less in diameter. In addition, we
elucidated the immunohistochemical characteristics in BCs
by using tissue microarray (TMA).
PATIENTS AND METHODS
Patients
During the period from November 1993 to March 1998,
a total of 665 patients with primary lung carcinoma were
treated by surgical resection at the National Cancer Center
Hospital East, Chiba, Japan. We reviewed the cases of the
201 consecutive patients in whom an adenocarcinoma of the
lung measuring 30 mm or less in diameter had been com-
pletely resected as candidates for inclusion in this study. All
patients signed an Institutional Review Board-approved writ-
ten informed consent. The tumors were staged according to
the tumor-node-metastasis classification of the International
Union Against Cancer (UICC)8 and were histologically sub-
typed and graded according to the third edition of the World
Health Organization guidelines.9 The median follow-up pe-
riod for these patients was 10.0 years. Survival time was
measured from the date of surgery.
Pathologic Review
All surgical specimens were fixed with 10% formalin
and embedded in paraffin. The tumors were cut at approxi-
mately 5-mm intervals, and serial 4-m sections were stained
with hematoxylin and eosin (HE) and by the Alcian blue-
periodic acid Schiff method to visualize cytoplasmic mucin
production and the Verhoeff-van Gieson method to visualize
elastic fibers. Lymphatic invasion and pulmonary metastasis
were evaluated in sections stained with HE. Vascular and
pleural invasion was evaluated by the Verhoeff-van Gieson
method. Two observers (Y.Y. and G.I.) who are unaware of
the clinical data independently reviewed all pathologic slides.
The histologic diagnoses were based on the revised World
Health Organization histologic classification. Tumor size was
measured as the maximal diameter on the cut sections of the
lung. The pathologic stage was determined according to the
UICC.
Definition and Evaluation of Tumor Budding
Isolated single cancer cells and clusters composed of
lesser than five cancer cells were defined as budding as
previously described.6 Such buddings are sometimes ob-
served in the fibrosis and collapse at the tumor–stromal
interface. To semiquantify budding, a field in which budding
intensity seemed to be maximal was selected on the slide, and
the number of budding in that field was counted using a 20
objective lens.10 Discordant results were resolved by a joint
review of the specimen through a multiheaded microscope.
Budding counts of 1 to 4 were rated as grade 1, counts of 5
to 10 as grade 2, and counts of 11 or more were as grade 3
(Figure 1). This classification was based on a previously
described classification.10
Construction of TMAs
We immunohistochemically stained the tumor of 20
patients whose tumors were with grade 3 budding during the
period from November 2004 to March 2009. The most
representative tumor areas were carefully selected and
marked on the HE-stained slide of donor tissue for construc-
tion of microarrays. We evaluated immunohistochemical pro-
files of the following components: I, BCs, and II, cancer cells
forming nests near budding cells (near BCs). TMAs were
constructed with a manual tissue-arraying instrument (Azu-
maya, Tokyo, Japan) as previously described.11 Specimens
were routinely sampled by taking a core sample of each
tumor from two different areas. A normal control TMA that
included samples from nonmalignant specimens of various
organs was used as a positive control.
Antibodies and Immunohistochemical Staining
In this study, the 14 antibodies used for immunohisto-
chemical staining are listed in Table 1, and the immuno-
chemical staining was performed as follows. TMA recipient
blocks were cut into 4-m sections and mounted on silane-
FIGURE 1. Histologic features of tumor budding. A, Tumor
budding in the area of fibrosis (hematoxylin and eosin [HE]
staining). B, Moderate magnification of the area boxed in A:
budding cells (BCs) are observed in the fibrotic stroma (HE
staining). C, Higher magnification of the area boxed in A.
Tumor budding is visible in the form of isolated small clus-
ters or single invading carcinoma cells with eosinophilic cy-
toplasm (HE staining). D, Cytokeratin AE1/3 immunostaining
of BCs.
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coated slides, with the initial sections HE stained to verify
histology. The sections were deparaffinized in xylene and
dehydrated in a graded alcohol series, and endogenous per-
oxidase was blocked with 3% hydrogen peroxide in absolute
methylalchol. Heat-induced epitope retrieval was performed
for 20 minutes at 95°C with a 0.02 mol/L concentration of
citrate buffer (pH 6.0) in the samples fixed with 10% forma-
lin. For laminin-52 antigen retrieval, sections were digested
with 0.1% protease type XXVII (Sigma, St. Louis, MO) for
20 minutes at room temperature. The slides were rinsed with
deionized water and incubated with primary antibodies. They
were then washed three times with phosphate-buffered saline
and incubated with the EnvisionSystem-HRP (DAKO,
Glostrup, Denmark). The reaction products were stained with
diaminobenzidine, and the sections were counterstained with
hematoxylin.
Calculation of Staining Scores
Immunostaining was scored based on the intensity of
staining and the percentage of cells that stained positively.
Whenever the reviewers scored the immunostaining differ-
ently, the slides were reviewed together and a consensus was
reached. The sections were classified according to staining
intensity as negative (total absence of staining), 1 (weak
staining), or 2 (strong staining). Staining scores were cal-
culated by multiplying the percentage of positive tumor cells
per section (0–100%) by the immunohistochemical staining
intensity and the scores obtained ranged from 0 to 200. The
staining scores obtained for the two core samples obtained
from the same specimen were averaged, and the result was
recorded as the score for that case. If one sample was lost,
the staining score was calculated from the data for the
remaining sample alone. Tumor-infiltrating macrophages
were identified by CD68 and CD204. After scanning the
immunostained section at low-power magnification, the
two areas with the greatest number of macrophages were
selected. Then the mean macrophage count was estimated
(per square millimeter).
Statistical Analysis
Cumulative survival rates were calculated by the
Kaplan-Meier method. The log-rank test was used to evaluate
differences between the survival curves. For comparing the
budding-positive group and the budding-negative group, the
2 test and t test were used. Several pathologic factors,
including those found associated with survival by the
univariate analysis, were subjected to multivariate analysis
using the Cox’s proportional hazards model. The Mann-
Whitney U test was used to compare the staining scores.
All calculations were performed with Stat View-J 5.0
software. Differences were considered significant when the
p value was less than 0.05.
RESULTS
Clinicopathologic Factors
Because 20 of the 201 cases were pure BAC (Nogu-
chi’s classification A or B), and no tumor budding was
observed in any of the pure BAC cases, we excluded them
from further analysis. The clinicopathologic characteristics of
the 181 patients in the remaining cases are summarized in
Table 2, and tumor budding was observed in 78 (43.1%) of
them. The clinicopathologic characteristics of the patients
and presence of tumor budding were analyzed for associa-
TABLE 1. Antibodies Used
Classification/Antibody Clone Dilution Source
Cellular adhesion molecule
-Catenin 14 1:100 BD Biosciences, San Jose, CA
E-Cadherin NCH-38 1:50 DakoCytomation, Carpinteria, CA
CD44 DF185 1:50 Novocastra, Newcastle upon Tyne, UK
Laminin-52 D4B5 1:1000 Chemicon, Temecula, CA
Growth factor receptor
EGFR H11 1:200 DakoCytomation, Carpinteria, CA
IGF-1R 24–31 1:100 Chemicon, Temecula, CA
Hypoxia-induced protein
CAIX Polyclonal 1:1000 Novus biologicals, Littleton, CO
GLUT-1 Polyclonal 1:200 Thermo Fisher Scientific, CA
Differentiation marker
Vimentin V9 1:50 DakoCytomation, Carpinteria, CA
SP-A PE10 1:50 DakoCytomation, Carpinteria, CA
TTF-1 8G7G3/1 1:50 DakoCytomation, Carpinteria, CA
Others
MMP-7 141–7B2 1:100 Daiichi fine chemical, Toyama, Japan
Macrophage-associated antigens
CD68 PG-M1 1:100 Dako, Glostrup, Denmark
CD204 SRA-E5 1:25 Transgenic, Kumamoto, Japan
EGFR, epidermal growth factor receptor; IGF-1R, insulin-like growth factor-1 receptor; CA IX, carbonic anhydrase IX; GLUT-1, glucose
transporter-1; SP-A, surfactant apoprotein-A; TTF-1, thyroid transcription factor-1; MMP-7, matrix metalloproteinase-7.
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tions, and significant associations were found between lymph
node metastasis (p  0.005), pathologic stage (p  0.001),
vascular invasion (p  0.003), lymphatic invasion (p 
0.009), pleural invasion (p  0.029), and the presence of
tumor budding.
Histologic Examination
Two cases were classified as the acinar subtype (1%),
two as the papillary subtype (1%), 17 as the solid adenocar-
cinoma with mucin subtype (9%), and the remaining 160 as
mixed subtype (89%). To test for associations between the
presence of tumor budding and histologic subtype, the 181
cases of adenocarcinoma were divided into four groups ac-
cording to the predominant histologic subtype: BAC predom-
inant subtype (80 cases; 44%), acinar predominant subtype
(15 cases; 8%), papillary predominant subtype (57 cases;
32%), and solid adenocarcinoma with mucin predominant
subtype (29 cases; 16%). Budding was detected in 78 cases,
21 (27%), 10 (13%), 34 (44%), and 13 (16%) in the predom-
inant BAC, acinar, papillary, and solid with mucin subtypes,
respectively. The predominant papillary subtype was signif-
icantly associated with the presence of tumor budding (p 
0.0023), and the predominant acinar subtype tended to be
associated with the presence, or tumor budding (p 0.0542).
However, predominant BAC subtype was significantly asso-
ciated with the absence of tumor budding (p  0.001). There
was no association between the predominant solid with mucin
subtype and the presence of budding (p  0.8075). Our
findings also showed that the presence of micropapillary
pattern (MPP) was significantly associated with the presence
of tumor budding (p  0.0138, Table 3).
Prognostic Significance of Tumor Budding
The overall 5-year survival rate of the budding-positive
group and the budding-negative group was 67.5% and 88.3%,
respectively, and the difference was significant (p  0.0057,
Figure 2A). The median follow-up time was 120 months.
Analysis according to the grade of tumor budding (grade 1–3)
showed that the outcome of the group with grade 1 tumor
budding was not significantly different from that of the group
without budding (p  0.2532, date not shown). In contrast,
the outcome of the group without tumor budding was signif-
icantly better than that of the group with grade 2 budding and
the group with grade 3 budding (p  0.0164 and p  0.0023,
respectively, Figure 2B).
Univariate analysis found tumor budding (grade 2  3,
p  0.0011), older age (p  0.0164), male (p  0.0116),
smoker (p  0.0116), lymph node metastasis (p  0.0001),
venous invasion (p  0.0001), lymphatic invasion (p 
0.0001), and pleural invasion (p  0.0001) to be the signif-
icant clinicopathologic prognostic factors for patients with
small-sized adenocarcinoma of the lung (Table 4). Multivar-
iate analysis was performed using these clinicopathologic
factors as covariates, and tumor budding (grade 2  3, p 
0.0301), older age (p  0.0139) lymph node metastasis (p 
0.0012), venous invasion (p  0.0058), lymphatic invasion
(p 0.0232), and pleural invasion (p 0.0017) were identified
as significant independent prognostic factors (Table 4).
TABLE 3. Correlation Between the Presence of Tumor
Budding and Predominant Histological Subtype (n  181)
Predominant
Histological Subtype All Cases
Tumor Budding
p
Budding
() (%)
Budding
() (%)
Bronchioloalveolar 80 21 (26) 59 (74)
Nonbronchioloalveolar 101 57 (56) 44 (44) 0.001
Acinar 15 10 (67) 5 (33)
Nonacinar 166 68 (41) 98 (59) 0.0542
Papillary 57 34 (60) 23 (40)
Nonpapillary 124 44 (35) 80 (65) 0.0023
MPP () 44 26 (59) 18 (41)
MPP () 157 52 (33) 105 (67) 0.0138
Solid 29 13 (45) 16 (55)
Nonsolid 152 65 (42) 87 (58) 0.8075
MPP, micropapillary pattern.
TABLE 2. Clinicopathological Characteristics of Patients
with Budding (n  181)
Characteristics
All Cases
(%)
Tumor Budding
p
Budding
() (%)
Budding
() (%)
No. of patients 181 78 (43) 103 (57)
Age (yr) 0.844
Median 62 62 62
Range 33–84 33–83 34–84
70 129 55 (43) 74 (57)
70 52 23 (44) 29 (56)
Gender 0.9523
Male 84 36 (43) 48 (57)
Female 97 42 (43) 55 (57)
Smoking status 0.330
Never smoker 98 39 (40) 59 (60)
Smoker 83 39 (47) 44 (53)
Tumor size (mm) 0.1114
Range 0.7–3.0 1.0–3.0 0.7–3.0
Mean 2.1 2.2 2.0
20 mm 70 25 (36) 45 (64)
20–30 mm 111 53 (48) 58 (52)
pN 0.005
pN0 145 55 (38) 90 (62)
pN1 or N2 36 23 (64) 13 (36)
Pathological stage 0.001
IA/IB 141 52 (37) 89 (63)
IIA/IIB/IIIA 40 26 (65) 14 (35)
Vascular invasion 0.003
Positive 58 34 (59) 24 (41)
Negative 123 44 (36) 79 (64)
Lymphatic invasion 0.009
Positive 60 34 (57) 26 (43)
Negative 121 44 (36) 77 (64)
Pleural invasion 0.029
Positive 41 26 (63) 15 (37)
Negative 140 52 (37) 88 (63)
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Immunohistochemical Profiles of BCs
We evaluated immunohistochemical profiles of BCs,
and near BCs. The staining scores are summarized in Table 5.
Cellular Adhesion Molecule
The staining score of CD44 did not have significant
difference between BC and near BC. However, the -catenin
staining scores of BC and near BC were 26.3 and 46.5,
respectively, and the staining score of BC was significantly
lesser than that of near BC (p  0.05). Similarly, E-cadherin
staining scores of BC and near BC were 61.0 and 104.8,
respectively, and the staining score of BC was significantly
lesser than that of near BC (p  0.05). Laminin-52 staining
scores in BC and near BC were 67.8 and 22.8, respectively,
and the score of BC was significantly higher than that of near
BC (p  0.05; Figure 3).
Growth Factor Receptor
There were no significant differences between BC and
near BC in the staining scores for epidermal growth factor
receptor (EGFR) and insulin-like growth factor-1 receptor.
Hypoxia-Induced Protein
There were no significant differences between BC and
near BC in the staining scores for carbonic anhydrase IX and
glucose transporter-1.
Macrophage-Associated Antigens
There were no significant differences between BC and
near BC in the number of tumor-infiltrating macrophages
identified by CD68 and CD204.
Differentiation Markers
There were no significant differences between the three
lesions in the staining scores for Vimentin. However, the
surfactant apoprotein-A (SP-A) staining scores of BC and
near BC were 2.8 and 23.8, respectively, and the staining
score of BC was significantly lower than that of near BC (p
0.05, Figure 3). The thyroid transcription factor-1 staining
score of BC and near BC were 47.5 and 63.3, respectively,
and there was no significant difference between BC and near
BC in the staining scores.
Other Staining Scores
There were no significant differences between the three
lesions in the staining scores for matrix metalloproteinase-7.
DISCUSSION
Tumor budding refers to the process of dissociation that
occurs at the invasive margin of colorectal cancer, and,
importantly, it has been shown to be an independent prog-
FIGURE 2. Cumulative overall survival curves. A, Cumula-
tive overall survival curves of 181 patients stratified by the
presence or absence of tumor budding. B, Cumulative
overall survival curves of 181 patients stratified by grade
of tumor budding.
TABLE 4. Impact of Potential Prognostic Factors on Survival of Patient in Adenocarcinoma of
Lung by Univariate and Multivariate Analysis (n  181)
Variable Univariate Analysis, p
Multivariate Analysis
Hazard Ratio 95% CI p
Tumor budding (grade 2  3) 0.0011 1.872 1.062–3.298 0.0301
Age 70 yr 0.0489 1.033 1.007–1.061 0.0139
Gender (male) 0.0116 1.892 0.803–4.457 0.1447
Smoking status (smoker) 0.0116 1.166 0.498–2.733 0.7237
Tumor size (2.0) 0.2959 — — —
Lymph node metastasis (N1, 2) 0.0001 2.485 1.433–4.307 0.0012
Venous invasion (positive) 0.0001 2.291 1.271–4.130 0.0058
Lymphatic invasion (positive) 0.0001 2.007 1.100–3.662 0.0232
Pleural invasion (positive) 0.0001 2.424 1.394–4.216 0.0017
CI, confidence interval.
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nostic marker with respect to local spread,12 lymph node
metastasis,5 distant metastasis,13 recurrence after curative
surgery,14 and survival after curative surgery.15 This is the
first study to evaluate tumor budding in adenocarcinoma of
the lung. We evaluated adenocarcinomas measuring30 mm
and observed tumor budding in 78 (43.1%) of the 181 cases,
only in invasive adenocarcinoma, indicating that tumor bud-
ding can occur even in small adenocarcinoma of the lung.
Our data showed that tumor budding in adenocarci-
noma of the lung was associated with several biologic factors:
lymph node metastasis, pathologic stage, vascular invasion,
lymphatic invasion, and pleural invasion. So that means the
presence of budding was a significant predictor of an unfa-
vorable outcome. In addition, multivariate analysis identified
tumor budding as prognostically significant in all stages as a
whole. This finding showed that budding is a histologic
independent prognostic factor in small-sized adenocarcinoma
of the lung. It has been reported that the presence of isolated
single cancer cells has been shown to be a prognostic marker
in small peripheral lung squamous cell carcinomas.16 More-
over, budding has also been pointed out in esophageal squa-
mous cell carcinoma and may be a useful prognostic indica-
tor.17 In this manner, budding aspect as a prognostic factor
has been attracting interest in many other cancer types. Thus,
budding may be a universal prognostic factor that does not
depend on cancer cell type.
The reason why tumor budding in lung adenocarcinoma
significantly associated with prognostic marker and poor
prognosis does not clarify. One of the convincing and satis-
factory explanations is that BC phenotype represent a distinct
component of tumor invasion as said in the colorectal carci-
noma.18 Using immunohistochemistry with the monoclonal
antibodies against podoplanin in TMA specimens, we found
that BC itself is actually in lymphatic vessel in 6 (30%) of the
20 budding positive cases (data not shown). These data may
in part explain the malignant potential of BCs.
The histologic examination revealed that the predomi-
nant papillary subtype was significantly associated with the
presence of tumor budding (p  0.0023), and a tendency for
the predominant acinar subtype to be associated with the
presence of tumor budding was also recognized (p 0.0542).
However, the predominant BAC subtype was significantly
associated with the absence of tumor budding (p  0.001),
and there was no association between the predominant solid
with mucin subtype and the presence of budding (p 
0.8075). These findings suggest that the biologic mechanism
by which budding is induced may vary with the histologic
subtype.
The analysis according to grade of tumor budding
(grade 1–3) showed that the outcome of the group with grade
1 tumor budding was not significantly different from that of
TABLE 5. Staining Scores and Number of Macrophage in
Budding Cells and Cancer Cells Forming Nests Near Budding
Cells
Classification/Antibody BC Near BC
Cellular adhesion molecule
-Catenin 26.3a 46.5
E-Cadherin 61.0a 104.8
CD44 17.5 21.8
Laminin-52 67.8a 22.8
Growth factor receptor
EGFR 48.3 50.0
IGF-1R 115.8 99.8
Hypoxia-induced protein
CAIX 32.8 27.8
GLUT-1 12.0 12.5
Differentiation marker
Vimentin 5.0 3.5
SP-A 2.8a 23.8
TTF-1 47.5 63.3
Others
MMP-7 47.8 42.5
Macrophage-associated antigens
CD68 8.0 6.2
CD204 11.3 10.9
About macrophages-associated antigens, tumor-infiltrating macrophages were
identified by CD68 and CD204 and macrophage count was estimated (per square
millimeter).
a The difference in staining scores between BC and near BC is statistically
significant (p  0.05).
BC, budding cells; near BC, cancer cells forming nests near budding cells; EGFR,
epidermal growth factor receptor; IGF-1R, insulin-like growth factor-1 receptor; CA IX,
carbonic anhydrase IX; GLUT-1, glucose transporter-1; SP-A, surfactant apoprotein-A;
TTF-1, thyroid transcription factor-1; MMP-7, matrix metalloproteinase-7.
FIGURE 3. Differences in the immunostaining for -cate-
nin, E-cadherin, laminin-52, and SP-A. A, -catenin stain-
ing: decreased membrane immunostaining was found in BC
(arrows) compared with tumor cells forming solid nests. B,
E-cadherin staining: decreased membrane immunostaining
was found in BC (arrows) compared with tumor cells form-
ing solid nests. C, Laminin-52 staining: increased cytoplasm
immunostaining was found in BC (arrows) compared with
tumor cells forming solid nests. D, SP-A staining: decreased
cytoplasm immunostaining was found in BC (arrows) com-
pared with tumor cells forming solid nests.
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the nonbudding group (p  0.2532). In contrast, the outcome
of the group without tumor budding was significantly better
than that of the group with grade 2 and the group with grade
3 tumor budding (p  0.0164 and p  0.0023, respectively).
Because there were no significant prognostic differences
between the group with no budding features and the group
with grade 1 budding, we performed univariate and multivar-
iate analyses to examine whether the presence with grade 2
3 budding could be an independent prognostic factor. The
current result revealed that five BCs or more is an indepen-
dent prognostic factor.
Recently, many researchers have reported that a num-
ber of transient molecular changes occur in the budding.18,19
There is experimental evidence linking laminin-52,20,21 and
E-cadherin22 expressions with tumor budding and malignant
invasion in colorectal carcinoma. In keeping with these data
of colorectal carcinoma as reported previously, our findings
also showed the reduced membranous expression of cellular
adhesion molecule, E-cadherin, and -catenin and increased
expression of laminin-52 in BCs. Moreover, Moriya et al.
studied the expression of laminin-52 immunohistochemi-
cally in small lung adenocarcinomas. They showed that
overexpression of laminin-52 was the only significant prog-
nostic factor and laminin-52 was preferentially localized in
the cytoplasm of tumor cells at the tumor-stromal interface at
which cancer cells that exhibited budding into the fibrous
stroma were frequently found.23 This finding is corresponding
to our data. Hida et al.24 reported that marked expression of
Cox-2 was often observed at the invasive front of lung
adenocarcinoma. Moreover, Niki et al.25 proved that frequent
coexpression of cox-2 and laminin-5 at the invasive front of
small-sized lung adenocarcinoma and their results suggest
that costimulatory mechanisms may exist that increase the
expression of cox-2 and laminin-5 at the invasive front and
that EGFR signaling could be one of the mechanisms. It
would be interesting to examine the staining score of phos-
pho-EGFR in BC and near BC.
The most remarkable immunohistochemical finding of
BCs was the reduced expression of differentiation markers
including SP-A. SP-A is produced by alveolar type II cells
and Clara cells. It is critically regulated by thyroid transcrip-
tion factor-1, a member of the Nkx2 family of homeodomain-
containing transcription factors, and is essential for lung
morphogenesis.26,27 SP-A plays a role in epithelial cell dif-
ferentiation and most BACs of the lung react positively for
SP-A. Brabletz et al. found a selective down-regulation of
Cdx2, which is one of the most specific factors of intestinal
differentiation, in BCs in colorectal carcinoma.28 Based on
the fact that SP-A plays a role in epithelial cell differentia-
tion, our data suggest that dissociated BCs in lung adenocar-
cinoma also have actually undergone dedifferentiation.
Tumor budding is thought to be closely related to the
epithelial–mesenchymal transition (EMT), because the mo-
lecular mechanism that leads to budding may be in part the
same as that of the EMT.18 Furthermore, because the EMT
and budding are largely restricted to the interface between
malignant epithelium and stromal elements at the invasive
margin, an increased sensitivity to mesenchymally drived
growth signals may trigger the EMT and/or budding process.
The characteristic of EMT phenotype are the reduced mem-
branous expression of E-cadherin and -catenin.29,30 And our
current results also suggest that BCs in adenocarcinoma of
the lung display in part EMT phenotype.
MPP is characterized by micropapillary tufts that are
isolated from the main tumor and seem to float in alveolar
spaces.31,32 and has been reported as an aggressive variant of
papillary subtype. Kawakami et al.33 demonstrated a close
association between invasion by small cell clusters in the
invasive portion of adenocarcinomas fibrotic foci and the
presence of MPP. Our findings also showed that the presence
of MPP was significantly associated with the presence of
tumor budding (p  0.0138). Despite morphologic similarity
of MPP and tumor budding, the immunophenotypes of these
are different. We have previously reported that the charac-
teristic of micropapillary component is an enhanced expres-
sion of hypoxic marker glucose transporter-1 and carbonic
anhydrase IX, whereas in BCs, we did not recognize such a
tendency. In addition, the reduced expression of E-cadherin
and -catenin is not found in MPP.34 Consequently, patho-
genesis of tumor budding might be different from MPP.
In conclusion, our data showed that tumor budding in
adenocarcinoma of the lung is a distinct morphologic feature
that has biologic and prognostic significance. Because one of
the morphologic representations of the phenotypic changes
of the malignancy that cause invasion and metastasis might
be budding, clarification of the molecular mechanism that
causes budding in lung adenocarcinoma will be important in
the future.
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